Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Terminated · Phase 1, Phase 2 · NCT04418661
Conditions: Metastatic Neoplasm
At a glance
- Research payments reported, 2025
- $32,852
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 65
About the trial
- Sponsor
- Sanofi (with Revolution Medicines, Inc., Mirati Therapeutics Inc.)
- Tested
- Vociprotafib (drug), Pembrolizumab (drug), Adagrasib (drug)
- Dates
- Started 2020-06-09; completion 2024-04-04
- Results posted
- Yes
Primary Objectives: * Part 1 * To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors. * To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in participants with solid tumors. * Part 2 * To determine the anti-tumor activity of SAR442720 in combination with pembrolizumab. * Part 3A * To define the MTD and RP2D for the combination of SAR442720 and adagrasib in participants with KRAS G12C NSCLC * To characterize the safety and tolerability of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC * Part 3B * To determine the anti-tumor activity of SAR442720 in combin…
From ClinicalTrials.gov, last updated 2025-05-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $32,852 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.